4/16
04:01 pm
allo
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
Low
Report
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
4/16
08:00 am
allo
Allogene Therapeutics (ALLO) was upgraded by JPMorgan Chase & Co. from "underweight" to "neutral".
Medium
Report
Allogene Therapeutics (ALLO) was upgraded by JPMorgan Chase & Co. from "underweight" to "neutral".
4/15
05:23 pm
allo
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? [Yahoo! Finance]
High
Report
Allogene Therapeutics (ALLO) Is Down 13.0% After $175M Equity Raise On ALPHA3 MRD Data Release – Has The Bull Case Changed? [Yahoo! Finance]
4/15
08:30 am
allo
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
High
Report
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
4/14
09:50 pm
allo
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
Low
Report
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
4/14
11:46 am
allo
Allogene Therapeutics (ALLO) had its price target raised by Argus from $1.60 to $3.85. They now have a "market perform" rating on the stock.
High
Report
Allogene Therapeutics (ALLO) had its price target raised by Argus from $1.60 to $3.85. They now have a "market perform" rating on the stock.
4/14
08:57 am
allo
Allogene Therapeutics (ALLO) had its "market perform" rating reaffirmed by Sanford C. Bernstein.
High
Report
Allogene Therapeutics (ALLO) had its "market perform" rating reaffirmed by Sanford C. Bernstein.
4/14
08:44 am
allo
Allogene Therapeutics (ALLO) had its price target raised by Citizens Jmp from $5.00 to $8.00. They now have a "market outperform" rating on the stock.
High
Report
Allogene Therapeutics (ALLO) had its price target raised by Citizens Jmp from $5.00 to $8.00. They now have a "market outperform" rating on the stock.
4/14
08:00 am
allo
Allogene Therapeutics (ALLO) had its price target raised by Robert W. Baird from $7.00 to $9.00. They now have an "outperform" rating on the stock.
High
Report
Allogene Therapeutics (ALLO) had its price target raised by Robert W. Baird from $7.00 to $9.00. They now have an "outperform" rating on the stock.
4/14
07:13 am
allo
Allogene Therapeutics (ALLO) had its "buy" rating reaffirmed by HC Wainwright.
High
Report
Allogene Therapeutics (ALLO) had its "buy" rating reaffirmed by HC Wainwright.
4/14
07:13 am
allo
Allogene Therapeutics (ALLO) had its "outperform" rating reaffirmed by Citigroup Inc..
High
Report
Allogene Therapeutics (ALLO) had its "outperform" rating reaffirmed by Citigroup Inc..
4/13
04:01 pm
allo
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
High
Report
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
4/13
07:30 am
allo
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Low
Report
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
4/10
04:02 pm
allo
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
High
Report
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
4/10
02:00 pm
allo
Allogene Therapeutics (ALLO) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.
Low
Report
Allogene Therapeutics (ALLO) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.
3/29
04:53 pm
allo
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026 [Yahoo! Finance]
Low
Report
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026 [Yahoo! Finance]
3/26
05:49 am
allo
Allogene Therapeutics (ALLO) was upgraded by Truist Financial Corporation to "strong-buy".
Medium
Report
Allogene Therapeutics (ALLO) was upgraded by Truist Financial Corporation to "strong-buy".
3/13
02:48 pm
allo
Allogene Therapeutics (ALLO) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.
Neutral
Report
Allogene Therapeutics (ALLO) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.
3/13
12:38 pm
allo
Allogene Therapeutics (ALLO) had its price target raised by Piper Sandler from $7.00 to $8.00. They now have an "overweight" rating on the stock.
Low
Report
Allogene Therapeutics (ALLO) had its price target raised by Piper Sandler from $7.00 to $8.00. They now have an "overweight" rating on the stock.
3/12
11:19 pm
allo
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Inc (ALLO) Q4 2025 Earnings Call Highlights: Financial Stability and ... [Yahoo! Finance]
3/12
10:04 pm
allo
Allogene Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/12
04:10 pm
allo
Allogene Therapeutics GAAP EPS of -$0.17 beats by $0.05 [Seeking Alpha]
Medium
Report
Allogene Therapeutics GAAP EPS of -$0.17 beats by $0.05 [Seeking Alpha]
3/12
04:02 pm
allo
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Medium
Report
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
3/3
10:52 pm
allo
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen [Yahoo! Finance]
Neutral
Report
Allogene Therapeutics Teases April ALPHA3 Futility Data, Details Autoimmune CAR-T Program at TD Cowen [Yahoo! Finance]
3/2
08:54 am
allo
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update [Yahoo! Finance]
Low
Report
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update [Yahoo! Finance]